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Abstract
Panic disorder patients are vulnerable to recurrent panic attacks. Two neurochemical hypotheses have been proposed to explain 
this susceptibility. The first assumes that panic patients have deficient serotonergic inhibition of neurons localized in the dorsal 
periaqueductal gray matter of the midbrain that organize defensive reactions to cope with proximal threats and of sympathomo-
tor control areas of the rostral ventrolateral medulla that generate most of the neurovegetative symptoms of the panic attack. 
The second suggests that endogenous opioids buffer normal subjects from the behavioral and physiological manifestations of 
the panic attack, and their deficit brings about heightened suffocation sensitivity and separation anxiety in panic patients, mak-
ing them more vulnerable to panic attacks. Experimental results obtained in rats performing one-way escape in the elevated 
T-maze, an animal model of panic, indicate that the inhibitory action of serotonin on defense is connected with activation of 
endogenous opioids in the periaqueductal gray. This allows reconciliation of the serotonergic and opioidergic hypotheses of 
panic pathophysiology, the periaqueductal gray being the fulcrum of serotonin-opioid interaction.
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The current concept of panic disorder (PD) as a distinct 
diagnostic category is based on the results originally reported 
by Klein and Fink (1) showing that chronic administration of the 
antidepressant agent imipramine led to improvement of patients 
who had recurrent episodes of extreme anxiety, named panic 
attack (PA). This finding led to the pharmacological distinction 
between PD and chronic anxiety, which has been adopted by 
contemporary psychiatric classifications. 
Although the PA is the hallmark of PD, its occurrence, 
alone, does not characterize the condition. The Diagnostic 
and Statistical Manual of Mental Disorders, 4th edition, Text 
Revision (DSM-IV-TR) (2) criteria for PD state that PAs 
must be associated with more than 1 month of subsequent 
persistent worry (anticipatory anxiety) about having another 
attack and about the consequences of the attacks, as well 
as with significant behavioral changes related to the attacks, 
chiefly avoidance of places or situations where having a PA 
is embarrassing and escape is difficult. When avoidance is 
generalized, the condition is called agoraphobia.
The PA is a period of intense fear in which 4 of 13 
defined symptoms develop abruptly, peaks in less than 10 
min from symptom onset, and usually subsides within 30 
min. The DSM-IV-TR (2) lists the following symptoms of a 
PA: palpitation, sweating, trembling, shortness of breath, 
choking, chest pain, nausea or abdominal distress, diz-
ziness, derealization or depersonalization, fear of losing 
control or of going crazy, fear of dying, numbness or tingling 
sensations, chills or hot flashes. Other symptoms that may 
occur are: diarrhea, cold hands, headache, insomnia, 
fatigue, intrusive thoughts, and ruminations. During the 
attack, patients often have an urge to flee or escape and a 
sense of impending doom, as though they are dying from 
suffocation or a heart attack.
The neural basis of anticipatory anxiety and avoidance 
is not fully understood, but there is sound preclinical and 
clinical evidence implicating the midbrain periaqueductal 
gray matter (PAG) in the genesis of PAs. The present review 
focuses on the modulation of PAs by neurotransmitters that 
work in the PAG, with emphasis on serotonin (5-HT) and 
endogenous opioids.
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PAG and panic
There is compelling experimental evidence obtained for 
both laboratory animals and human subjects supporting the 
participation of the PAG in PAs (3). Electrical or chemical 
stimulation of the dorsal part of the PAG (dPAG), mainly 
the dorsolateral column, elicits behavioral changes that are 
reminiscent of a PA. Also, electrical stimulation of the dPAG 
in human patients undergoing neurosurgery evokes feelings 
of dread accompanied by neurovegetative manifestations 
that overlap the symptoms of a PA (Table 1).
More recently, the participation of the PAG in panic 
has been investigated using structural and functional neu-
roimaging. In the structural studies, the soundest evidence 
comes from results obtained with voxel-based morphometry 
(VBM). This is an automated method of brain segmenta-
tion into gray matter, white matter and cerebrospinal fluid 
compartments that allows the investigation of differences 
in regional volumes along the whole brain. Using the VBM 
technique, Protopopescu et al. (4) have described an in-
crease in gray matter volume of the midbrain and rostral 
pons, comprising the PAG, in panic patients compared to 
healthy controls. In a similar study by our research group 
(5), we have also found a relative increase in gray matter 
volume of midbrain and pons in panic patients compared 
to healthy subjects. A further study (6) was able to assess 
separately the volume of gray matter of the dorsal and of 
the ventral midbrain. The results obtained showed that the 
relative volume of the dorsal midbrain was larger in the PD 
group compared to healthy controls, while the volume of 
the ventral midbrain was not. A significant positive correla-
tion was found between relative dorsal midbrain volume 
and severity of PD symptoms, and a significant negative 
correlation between relative dorsal midbrain volume and 
quality of life scores in PD patients. These findings clearly 
implicate the dorsal midbrain, where the dPAG lies, in the 
pathophysiology of PD.
Regarding functional studies, 
the detection of metabolic dysfunc-
tions in a small structure like the 
PAG is hampered by the limitations 
of current neuroimaging tech-
niques. Despite this shortcoming, 
some studies have reported ab-
normalities in the midbrain of panic 
patients. Using H215O positron 
emission tomography (PET) on 
lactate-induced panic attacks (see 
below), Reiman et al. (7) reported 
activation of several brain areas 
that organize defensive behavior 
including the anterior temporal lobe 
and an area subjacent to the supe-
rior colliculi, probably the PAG. A 
similar study using cholecystokinin 
tetrapeptide (CCK-4) administration to induce PAs showed 
activation of the hypothalamus and the PAG (8).
Another PET study investigated regional glucose uti-
lization in patients with PD before and after cognitive be-
havior therapy (CBT) (9). In 11 of 12 patients who showed 
improvement, decreased glucose utilization was detected 
in the right hippocampus, left anterior cingulate cortex, left 
cerebellum, and midbrain-pons, whereas increased glucose 
utilization was seen in the bilateral medial prefrontal cortex 
(PFC). More relevant to the present discussion is the finding 
of significant correlations between the percent change of 
glucose utilization in the left medial PFC and changes of 
anxiety and of the agoraphobia-related subscale of the Panic 
Disorder Severity Scale, as well as between the percent 
change of glucose utilization in the midbrain and the number 
of PAs during the 4 weeks before each scan.
The last results indicate that anticipatory anxiety cor-
relates with activation of the medial PFC while the PA is 
associated with PAG activation. This concept is strongly 
supported by the findings of a paradigmatic experiment 
with healthy volunteers using functional magnetic reso-
nance imaging (fMRI) (10). In the experimental session, 
a virtual predator is programmed to chase a virtual prey 
within the alleys of a labyrinth visualized by the participant 
on a video screen. By manipulating a keyboard to move a 
triangle representing the prey, the participant was able to 
avoid a virtual predator, represented by a red dot, with the 
ability to chase, capture and inflict pain. There were two 
levels of threat, consisting of either one or three electric 
shocks being administered to one finger when the virtual 
prey was caught. The results obtained showed that brain 
activity shifted from PFC areas (cingulate and orbitofrontal 
cortices and anterior ventromedial PFC) to the PAG as the 
predator grew closer to the prey. When the predator was 
distant, the PFC and the lateral amygdala were activated, 
more clearly when the expected threat level was low. When 
Table 1. Similarities of the symptoms of a panic attack and the effects of electrical stimulation 
of the periaqueductal gray matter (PAG) in humans and rats. 
Panic attack symptoms PAG stimulation in humans PAG stimulation in rats
Extreme fear and distress Dread, terror Switches off stimulation
Urge to flee Urge to flee Flight
Palpitation Tachycardia Tachycardia
Sweating Sweating
Tremor Sensation of vibration
Shortness of breath or choking Hyperventilation Tachypnea
Apnea Hyperventilation
Chest pain or discomfort Chest and heart pain
Nausea or abdominal discomfort Urge to urinate Micturition
Defecation
Chills or hot flushes “Burn/cold” sensations
Modified from Del-Ben and Graeff (3).
368 F.G. Graeff
www.bjournal.com.brBraz J Med Biol Res 45(4) 2012
the predator was close to the prey, the central amygdala 
and the PAG were activated. This activation was maximal 
when the highest level of pain was anticipated. Moreover, 
the degree of PAG activation was positively correlated with 
the reported intensity of fear and decreased confidence of 
escape. A further study (11) used a similar experimental 
setting to test McNaughton and Corr’s two-dimensional 
theory of fear/anxiety (12). One dimension is defensive 
distance and the other defensive direction, which distin-
guishes fear from anxiety. In fear, there is only motivation 
to escape or to avoid the danger source, whereas in anxiety 
this motivation is in conflict with an opposite tendency to 
approach the same source of danger. As a model of fear, 
the escape task described above was used while anxiety 
was assessed after the virtual prey had been caught by 
the predator and the persecution was stopped. In addition 
to regional activity, the fMRI also explored connectivity 
among brain structures. The results showed that the anxiety 
condition activated the medial PFC and actively inhibited 
PAG activation. In contrast, when the predator was close 
to the pray the PAG was activated and PFC activation was 
inhibited. These results support the view that anxiety is 
mainly integrated in the forebrain, whereas panic is chiefly 
organized in the midbrain.
5-HT and Panic
Among several neurotransmitters that operate in the 
PAG, 5-HT is believed to play a key role in PAs for at least 
two reasons: 1) a theoretical construct about the role of 
5-HT in defense proposes that 5-HT inhibits PAG neural 
networks that coordinate defense reactions against proximal 
danger and that these networks are the same that bring 
about the PA (13,14) and 2) antidepressant drugs that are 
used to treat PD are likely to act by enhancing the action 
of 5-HT in the brain (15).
The modulation of defense by 5-HT in the dPAG of the 
rat has been thoroughly reviewed elsewhere (16-18). The 
evidence supporting the hypothesis that 5-HT inhibits aver-
sion generated by electrical stimulation of the dPAG may be 
summarized as follows: 1) systemically administered drugs 
that enhance the central action of 5-HT impair behavioral 
responses that either decrease or terminate electrical cur-
rent applied to the dPAG; 2) injection into the dPAG of 5-HT 
or drugs that stimulate 5-HT1A and/or 5-HT2A receptors in-
creases the least electrical current intensity that elicits flight 
with dPAG stimulation (aversive threshold); 3) treatments 
that release 5-HT into the dPAG have a similar antiaversive 
effect; 4) escape from the open arm of the elevated T-maze 
(ETM, see description in the “5-HT and Opioids section”), a 
task that activates the dPAG and has been pharmacologi-
cally validated as an animal model of panic, is impaired 
by systemically or intracerebrally administered drugs that 
enhance the action of 5-HT, including several antidepres-
sants that are used to treat PD; 5) the same escape task 
is facilitated by either systemic injection of the panicogenic 
agent CCK-8s or intra-PAG administration of the similar 
agent CCK-4; 6) the inhibitory effect of antidepressants on 
ETM escape is antagonized by pretreatment with a selec-
tive 5-HT1A receptor blocker injected into the dPAG; 7) the 
sensitivity of 5-HT1A and 5-HT2A receptors is heightened 
following chronic (daily injection for 21 days), but not acute, 
treatment with antipanic drugs, including antidepressants 
and the panicolytic benzodiazepine derivative alprazolam, 
a drug that acts primarily on GABAA receptors.
The concept that 5-HT inhibits defensive reactions 
elaborated in the dPAG is central to the hypothesis that 5-HT 
has a dual role in defense (13). This theoretical construct 
was devised to explain seemingly inconsistent effects of 
5-HT-acting drugs measured in animal models of anxiety: 
in punishment or inhibitory avoidance tests, response 
suppression is attenuated by drugs that reduce the action 
of 5-HT in the brain, an effect shared by typical anxiolytic 
agents; conversely, pro-5-HT drugs enhance the behavioral 
inhibition caused by the same tests. This evidence led to 
the suggestion that 5-HT exerts an anxiogenic action in the 
brain. Pointing to the opposite direction, however, the results 
described above with escape from aversive stimulation show 
that 5-HT-enhancing drugs impair escape, indicating that 
5-HT decreases anxiety. To circumvent this inconsistency, 
we suggested (13) that these two experimental paradigms 
represent different defense strategies, as defined by the 
ethoexperimental studies carried out by Blanchard and 
Blanchard (19): inhibitory avoidance or conflict tests would 
engage forebrain neural networks that organize defense 
against potential threats, whereas escape tasks engage 
neural circuits that control primitive defense reactions 
against proximal threats, which are mainly integrated in the 
hindbrain, particularly in the dPAG. Since inhibitory avoid-
ance is facilitated while escape is inhibited by 5-HT, this 
neurotransmitter is assumed to enhance defense against 
potential danger, but to restrain proximal defense. This 
organization would allow the animal to withhold conspicu-
ous defense reactions, such as running and jumping, in 
situations where the predator is absent (potential threat) or 
at a safe distance from the prey (distant threat).
Taking it a step further, Deakin and Graeff (14) integrated 
defense strategy, normal emotion and related psychiatric disor-
der with drug responses and the underpinning brain structures. 
The resultant organization is summarized in Table 2.
Extending the preceding argument, Deakin and Graeff 
(14) suggested that 5-HT enhances anxiety by acting on 
the amygdala and PFC, but inhibits panic by acting on the 
dPAG. As described above, the pharmacological results 
with electrical stimulation of the dPAG and the escape task 
in the ETM are in agreement with the latter assumption, as 
is the hyperreponsiveness of 5-HT1A and 5-HT2A receptors 
localized in the dPAG caused by drug regimens that are 
clinically effective on PD - indicating that 5-HT is relevant 
for the therapeutic outcome (15).
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The next question is whether serotonergic mechanisms 
operating in the dPAG are involved in the pathophysiology 
of PD. The results of a preclinical study by Johnson et 
al. (20) indicate that they are. In their experiments, rats 
were chronically infused with the GABA synthesis inhibitor 
l-allylglycine through a minipump placed inside the dorso-
medial hypothalamus, a procedure that makes the animals 
responsive to lactate, like PD patients. Controls were simi-
larly infused with the inactive enantiomer, d-allylglycine. The 
activation of brain structures was assessed by the c-Fos 
technique, and the results obtained showed that lactate 
increased c-Fos expression in serotonergic neurons situ-
ated in the ventrolateral part of the dorsal raphe nucleus 
and ventrolateral PAG of control, but not panic-prone, rats. 
The distribution of lactate-sensitive serotonergic neurons 
in control rats overlaps the set of neurons activated by 
stressful situations previously described by Johnson et al. 
(21), which project to both the dPAG and sympathomotor 
control areas of the rostral ventrolateral medulla. The former 
projection is thought to inhibit the behavioral responses and 
the latter, the neurovegetative changes evoked by lactate 
in panic-prone rats. It has also been hypothesized that 
such serotonergic neurons normally limit neurovegetative 
and behavioral responses to innocuous interoceptive and 
exteroceptive stimuli, and that dysfunction of this seroton-
ergic system increases vulnerability to PAs in animals as 
well as humans (20).
In summary, the serotonergic hypothesis of PD 
pathophysiology proposes that panic patients have deficient 
serotonergic inhibition of neurons localized in the dPAG that 
organize defensive reactions to cope with proximal threats 
and of sympathomotor control areas of the rostral ventrolat-
eral medulla that bring about most of the neurovegetative 
symptoms of the PA. Indirect human experimental evidence 
is compatible with this view. The first line of evidence is 
based on studies using the simulated public speaking (SPS) 
test, in which the participant is required to speak in front of 
a video camera while looking at her/his image on a video 
screen. This procedure evokes anticipatory anxiety before 
the speaking task begins, as well as fear during speech 
preparation and performance. This distinction is based on 
pharmacological studies showing that anticipatory anxiety 
is reduced by benzodiazepine anxiolytics, but fear of public 
speaking is resistant to anxiolytics. In turn, fear of public 
speaking is affected by drugs that act primarily on 5-HT, 
the pharmacological profile of speaking fear being similar 
to that of PD. For this reason, SPS is assumed to engage 
the same neural networks that control the PA (22).
With a modified SPS test, in which healthy volunteers 
had their speech recorded on an audio tape, we showed 
that the nonselective 5-HT receptor antagonist metergoline 
increased subjective anxiety, measured by a self-rating scale 
before and after the speaking stress, and also reduced 
the response to speech preparation and performance 
(23). Several years later, Del-Ben et al. (24) observed that 
panic patients likewise showed a higher degree of antici-
patory anxiety and a lesser response to speaking stress 
than healthy controls. This similarity led to the suggestion 
that PD patients lacked endogenous 5-HT inhibition, thus 
becoming more vulnerable to PAs.
Further evidence comes from two experimental stud-
ies (25,26) using a human version of the mouse defense 
test battery, a procedure that assesses behavioral indexes 
of anxiety and fear/panic separately and that has been 
pharmacologically validated (27). In the task designed to 
represent a potential threat, healthy volunteers use a force-
sensing joystick to control the speed of a green dot cursor 
that moves within a vertical alley on a video screen, when 
it is trapped between two immobile red dot threat stimuli. 
The magnitude of approach-withdrawal oscillations during 
this phase was used as a measure of anxiety. In the task 
representing an actual threat, the average speed of the 
cursor while the participant was escaping from the pursuit 
by a single red dot threat stimulus was used as an index 
of fear. The results of the first study (25) showed that the 
benzodiazepine anxiolytic lorazepam significantly reduced 
approach-withdrawal oscillations during the first task, sup-
porting the hypothesis that this task represents anxiety. In 
Table 2. Antipredator defense strategies, anatomical basis, related emotions, anxiety disorders, and their drug treatment.
Threat Defense strategy Critical brain structures Emotion Disorder Drug treatment
Uncertain 
Conflict
Risk assessment
Behavioral inhibition
PFC
Septum-hippocampus
Amygdala
Anxiety GAD Anxiolytic
Antidepressant
Anticipated (CS) Freezing (no exit) Amygdala
vPAG
Anxiety Anticipatory anxiety Anxiolytic
Antidepressant
Avoidance Amygdala Conditioned fear Specific phobia None
Distal (US) Escape Medial hypothalamus Unconditioned fear Specific phobia None
Proximal (US) Flight or immobility dPAG Dread PD Antidepressant
CS = conditioned stimulus; US = unconditioned stimulus; PFC = prefrontal cortex; vPAG = ventral periaqueductal gray; dPAG = dorsal 
periaqueductal gray; GAD = generalized anxiety disorder; PD = panic disorder. Modified from Deakin and Graeff (14).
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contrast, the same drug did not change the performance of 
the escape task, hypothetically related to fear. In the second 
study (26), the escape task was measured in participants 
who differed in genetic risk for PD. The genetic risk factor 
used was the C allele of the 102T/C single-nucleotide poly-
morphism (rs6313) within the serotonin 2A receptor gene 
(HTR2A) on chromosome 13q14.2. This allele is known 
to be associated with increased susceptibility to pure but 
not comorbid PD, as well as to an increased magnitude of 
panic symptoms. The main finding was that carriers of the 
C risk allele showed significantly greater escape intensity 
than individuals devoid of this allele. This molecular genetic 
investigation, together with the preceding pharmacological 
results, support the hypothesis that PD stems from altera-
tions in the brain systems governing escape behavior, which 
are modulated by 5-HT.
Although the evidence presented above does not per-
mit anatomical localization, reported neuroimaging results 
have suggested anomalies of 5-HT neurotransmission in 
the midbrain of panic patients. The study most pertinent 
to the present discussion was conducted by Maron et al. 
(28) and measured the serotonin membrane transporter 
(5-HTT) binding in the brain of patients with PD by means 
of single-photon emission computed tomography (SPECT) 
with a radioligand that specifically labels the 5-HTT. Patients 
with symptomatic PD had a significantly decreased 5-HTT 
binding in the midbrain, temporal lobes and thalamus 
compared to normal controls. Patients with PD in remission 
had normal 5-HTT binding in the midbrain and temporal 
lobes, but still showed a significant decrease in thalamic 
5-HTT. The authors suggested that such reduced density 
of brain 5-HTT may reflect a deficit of neuronal 5-HT, or a 
compensatory process in the 5-HT system attempting to 
increase the availability of synaptic 5-HT. The deficits in 
the midbrain and in the temporal lobes may be related to 
clinical symptoms, since they were absent in the patients 
in remission, whereas the reduced 5-HTT in the thalamus 
may rather be a marker of interoceptive sensitivity and 
anticipatory anxiety.
There is also a reported PET study (29) with a selec-
tive 5-HT1A receptor (5-HT1AR) radioligand that assessed 
central 5-HT1AR binding in symptomatic PD patients 
compared to matched healthy controls. Panic patients 
showed lower 5-HT1AR density in the median raphe and 
in the anterior and posterior cingulate gyrus than controls. 
These results provide in vivo evidence for the involvement 
of 5-HT1ARs in the pathophysiology of PD. Since the dPAG 
receives serotonergic fibers from the dorsal raphe nucleus, 
the abnormality of 5-HT1AR in the raphe area may result 
in functional changes in the dPAG neurons that control 
proximal defense, hypothetically involved in PAs.
Opioids and Panic
The connection between opioids and PD has been made 
within the amplified false suffocation alarm (FSA) theory 
proposed by Preter and Klein (30). In the original version 
of the FSA theory (31), Klein proposed that the spontane-
ous PA is due to the misinterpretation by a hypersensitive 
CO2 detector that triggers a suffocation alarm, producing 
sudden respiratory distress. Among other arguments, Klein 
highlighted the facts that dyspnea, air hunger and urge to 
flee are cardinal symptoms of PAs, and that PD patients 
present baseline respiratory abnormalities and a higher rate 
of comorbid and antecedent respiratory diseases.
Critical tests of the FSA theory have been made with 
chemical panicogenic agents that induce PAs in PD patients 
at rates far higher than in healthy individuals. Among these 
challenges, lactate and CO2 inhalation at high concentra-
tions are the most selective panicogens (32). Both treat-
ments are assumed to elevate intracellular pCO2, triggering 
the suffocation alarm (31). A significant finding from this 
line of research was the verification that the PA induced by 
either lactate or CO2, stressful as it is, does not activate the 
hypothalamic-pituitary-adrenal (HPA) axis, similarly to the 
natural PA (33). This establishes a connection between the 
FSA and the Deakin-Graeff theories, since it has been shown 
that the speaking fear in the SPS test, which is assumed to 
engage the same neural networks involved in the PA (see 
above), also does not increase salivary or plasma levels of 
cortisol, in contrast to anticipatory anxiety (34,35).
Similar results have been obtained in animal models of 
panic. Electrical stimulation of the rat dPAG eliciting freezing 
or flight behavior did not increase the plasma concentration 
of the stress hormones adrenocorticotropin (ACTH) and 
prolactin; even a 5-min stimulation of the dPAG at the flight 
threshold intensity did not change ACTH levels significantly 
(36). Nevertheless, contrary results have also been reported 
(37). In the ETM, performance of the escape task, related 
to panic, did not release corticosterone into the blood 
stream; in contrast, the avoidance task, related to anxiety, 
increased the plasma level of the same stress hormone 
(38). Since the HPA axis is not activated by manipulations 
that are thought to activate the suffocation alarm system 
as well as those that are believed to stimulate the dPAG, 
it is possible that suffocation may engage the dPAG in the 
same way as other kinds of proximal threat, a notion already 
acknowledged by Deakin and Graeff (14).
Supporting the last view, preclinical results obtained 
by Schimitel et al. (39) showed that anoxia produced by 
sublethal doses of iv potassium cyanide (KCN) produced 
freezing and flight behavior and potentiated panic-like 
responses in rats elicited by PAG electrical stimulation. 
Moreover, KCN-evoked defensive responses were either 
abolished or markedly attenuated following electrolytic 
lesion of the caudal PAG. In contrast, exposure to 13% 
CO2 produced only a significant reduction of grooming and 
attenuated PAG-evoked panic-like responses. However, 
exposure to either 8 or 13% CO2 produced a marked dose-
dependent facilitation of KCN-induced flight behavior. It was 
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suggested that the caudal PAG harbors an anoxia-sensitive 
suffocation alarm system, the dysfunction of which renders 
the rat hyperresponsive to CO2.
The amplified FSA theory emphasizes a role for en-
dogenous opioids in both respiratory misregulation and 
separation distress - another factor that is associated with 
vulnerability to PA (40). As to respiration, several reported 
results have shown that endogenous opioids are activated 
in hypoxic or hypercapnic respiratory distress, decrease 
respiratory sensitivity to CO2, and increase survival under 
hypoxic and hypercapnic conditions (for references, see 
Preter and Klein, 30). The case for opioids and separation 
distress is more complex. Klein and Fink (1) found that 50% 
of hospitalized patients with a diagnosis of agoraphobia 
reported severe early separation anxiety that frequently 
prevented school attendance, and in this group panic 
was often precipitated by separation or bereavement. As 
a consequence, they hypothesized a developmental 
pathophysiological link between separation anxiety and 
PD with subsequent agoraphobia. Supporting this sugges-
tion, a controlled, long-term, direct, blind, clinical interview 
follow-up carried out by Klein (40) in separation-anxious, 
school-phobic children showed that the only significant 
finding was an increased PD rate later in life.
Again, the increased susceptibility to PA determined by 
early separation may also be mediated by PAG mechanisms, 
since a preclinical study (41) showed that rats separated 
from their mothers at an early age - 3 h per day during the 
21 days of lactation - became more sensitive to elicitation 
of panic-like behavior by electrical stimulation of the dPAG 
on the 65th day postpartum. Compared to controls, sepa-
rated rats showed a marked reduction in the thresholds for 
immobility, exophthalmus, trotting, galloping, and jumping 
elicited by electrical dPAG stimulation.
The connection between separation distress and opioids 
is based on the research by Panksepp et al. (42), who have 
systematically studied the neurobiology of social bonding 
and separation in laboratory animals. Among their findings 
stands the verification that low doses of the exogenous opi-
ates oxymorphone and morphine reduce crying and motor 
agitation during brief periods of social isolation in puppies. 
Since such effects could be obtained in the absence of any 
gross behavioral change, it was suggested that brain opiates 
may regulate the emotions arising from social separation 
(43). Similar results have been reported in primates (44), with 
a low dose of morphine significantly decreasing separation 
distress vocalizations in rhesus monkeys without changing 
motor activity. Furthermore, this effect was blocked by a 
low dose of the opioid receptor antagonist naloxone and a 
higher dose of naloxone increased distress calls by itself, 
suggesting a regulatory role of endogenous opioids. Con-
necting separation-distress calls with panic are J.P. Scott’s 
findings, in beagles, showing that among several psycho-
active drugs tested only the antipanic agent imipramine 
selectively reduced distress vocalizations at non-sedating 
doses (quoted by Preter and Klein, 30).
Assuming the central regulatory role of opioids in dis-
ordered breathing and separation distress, the amplified 
FSA theory proposes that there is a functional deficit of 
endogenous opioids in PD (30). For empirical validation of 
this theory, human experimental studies were carried out 
to verify whether pretreatment with the opioid antagonist 
naloxone would render healthy volunteers as susceptible to 
lactate-induced PA as PD patients. The results of an open 
pilot study showed that in 8 of 12 normal subjects, infusion 
of a high dose of naloxone (2 mg/kg) followed by lactate 
caused respiratory changes similar to those observed during 
clinical PAs. Four of the subjects that received the same 
lactate injection after placebo did not show tidal volume 
increment (45). Even more convincing, a further study 
used randomized cross-over sequences of the same dose 
(2 mg/kg) of intravenous naloxone followed by lactate, or 
saline followed by lactate, given to 25 healthy volunteers. 
Respiration was objectively measured, and subjective symp-
tomatology was also recorded. Whether separation and 
personal loss during childhood affected naloxone-induced 
respiratory changes was also explored. As expected, the 
results showed that naloxone pretreatment enhanced tidal 
volume and the symptomatic response to lactate. In addi-
tion, naloxone potentiation of lactate was less marked in 
volunteers who had experienced childhood parental loss, 
possibly because the endogenous opioid function was 
already reduced in these subjects (46). Altogether, these 
results support the hypothesis that endogenous opioids 
buffer normal subjects from the behavioral and physiologi-
cal effects of lactate and, conversely, their deficit may bring 
about the suffocation sensitivity and separation anxiety 
shown by panic patients (30).
5-HT and Opioids
Summing up the evidence discussed above, it may 
be concluded that the susceptibility to PA of PD patients 
is due to a functional deficit of either a serotonergic or an 
opioidergic system that restrains PAs in healthy individu-
als. Assuming the pivotal role of the dPAG in the regulation 
of PAs, the question arises of whether 5-HT and opioids 
are able to interact within this brain area. To investigate 
the latter possibility, a series of experiments were carried 
out by Roncon et al. (47), in which rats were tested in the 
ETM model of anxiety and panic. The method used has 
been described fully before (see, e.g., Zanoveli et al., 48). 
Briefly, the ETM has three arms of equal dimensions; one 
arm, enclosed by walls, perpendicular to two opposed open 
arms. For two consecutive days, the animals are gently 
handled for 5 min, and on the last day, 24 h before the test, 
each animal is pre-exposed to one of the open arms of the 
ETM for 30 min. On the test day, following drug treatment, 
the rat is placed at the end of the enclosed arm facing the 
intersection of the arms. The time taken to leave this arm 
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with the four paws is recorded (Baseline). The same mea-
surement is repeated twice at 30-s intervals (Avoidance 1 
and Avoidance 2). Following avoidance training (30 s), the 
rat is placed at the end of the open arm to which it had been 
previously exposed, and the latency to leave this arm with 
the four paws is recorded three consecutive times (Escape 
1-3) at 30-s inter-trial intervals. A cut-off time of 300 s is set 
for the avoidance and escape latencies.
The first experiment carried out by Roncon et al. (47) 
tested whether pretreatment with an intraperitoneal injec-
tion of naloxone (1 mg/kg) changes the effect of chronic 
treatment (10 mg/kg, ip, daily for 21 days) with fluoxetine 
on ETM performance. The results showed that fluoxetine 
significantly increased escape latency, which is interpreted 
as a panicolytic-like effect. In addition, naloxone did not af-
fect escape, but when given before fluoxetine it antagonized 
its panicolytic effect. This result suggests that the antipanic 
effect of the serotonergic antidepressant is dependent on 
endogenous opioids.
Since the antipanic action of fluoxetine is likely to be 
exerted in the dPAG (15), the second experiment tested 
whether the effect of systemic fluoxetine on escape latency 
could be antagonized by naloxone microinjected into the 
dPAG. The results showed that 0.2 μg (in 0.5 μL) of intra-
dPAG naloxone did not affect the escape latency, but was 
able to antagonize the antipanic effect of fluoxetine when 
given as pretreatment. This result suggests that the anti-
panic effect of fluoxetine involves endogenous opioids that 
operate within the dPAG.
Because the antipanic effect of fluoxetine is likely to be 
due to increased serotonergic function in the dPAG (48), 
the third experiment assessed the influence of naloxone 
on the antipanic effect of 5-HT when both were injected 
into the dPAG. The results showed that the escape impair-
ment produced by 5-HT (20 nmol/0.5 μL) was attenuated 
by previous administration of naloxone (0.2 μg/0.5 μL). 
This result indicates that the antipanic effect of 5-HT in the 
dPAG needs activation of local endogenous opioids to be 
expressed.
It is worth remarking that the effects of this drug on the 
ETM were specific for escape, since no significant changes 
occurred in either the avoidance task or locomotion, the 
latter being measured inside a square arena soon after 
the ETM test. 
The main results of the study by Roncon et al. (47) are 
shown in Figure 1. 
Further research is needed to establish the cellular 
and molecular basis of the interaction between 5-HT 
and endogenous opioids that is likely to take place in the 
dPAG. Nevertheless, there are some clues that deserve 
consideration. For instance, Preter and Klein (30) remarked 
that only high doses of naloxone were able to potentiate 
the panic-inducing effect of lactate in healthy volunteers, 
and since naloxone blocks the μ opioid receptor at lower 
concentrations than those needed to block the δ receptor, 
they suggested that the latter receptor type was mainly 
involved in the panic-buffering action of endogenous opi-
oids. Interestingly, Leu-enkephalin has a higher affinity for 
δ than for μ opioid receptors, and an interaction between 
this endogenous opioid and 5-HT has already been re-
ported (49). In this study, the antinociceptive effect induced 
by 5-HT microinjected into the nucleus accumbens was 
Figure 1. Naloxone (Nal) antagonism of the antipanic effect of 
serotonergic drugs in the one-way escape task performed on the 
elevated T-maze. Panel A, Nal administered intraperitoneally (ip) 
= 1 mg/kg naloxone, ip; Fluo = 10 mg/kg, ip, of fluoxetine daily for 
21 days; Sal = saline; Veh = vehicle. Panel B, Nal (DPAG) = 0.2 
μg naloxone into the dorsal periaqueductal gray. Panel C, 5-HT 
(DPAG): 8 μg serotonin intra-DPAG. *P < 0.05 compared to all 
other groups (Fisher post hoc test). N = 6-8 rats. Data are reported 
as means ± SEM of combined measures of the three escape tri-
als calculated from data reported by Roncon et al. (47).
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blocked by naloxone injected into the same site. In ad-
dition, it was verified that the antinociception elicited by 
intra-accumbens injection of [d-Ala2, d-Leu5]-enkephalin 
was not affected by cinanserin, a 5-HT blocking agent. 
It was suggested that 5-HT activates an enkephalinergic 
mechanism within the nucleus accumbens, resulting in the 
antinociceptive effect. Therefore, Leu-enkephalin may be 
a worthy candidate for participating in the serotonin-opioid 
interplay that we are suggesting to occur in the dPAG. 
Nevertheless, β-endorphin is another possibility to be kept 
in mind, since a neurohistochemical study detected the 
presence of varicose fibers positive for β-endorphin and/or 
Leu-enkephalin in the rat dPAG (50). Because varicosities 
are characteristic of monoaminergic nerve fibers (51), the 
possibility of 5-HT and opioids being cotransmitters (52) 
should also be considered.
Conclusion
The evidence reviewed here suggests that the vulner-
ability to PAs that characterizes PD may be the result of 
faulty buffering mechanisms. Two of them have been hy-
pothesized on the basis of empirical evidence gathered in 
experimental animals and in human beings. The first is a 
serotonergic input that restrains neurons in the dPAG that 
organize behavioral reactions to cope with a proximal threat, 
and that inhibits sympathomotor control areas of the rostral 
ventrolateral medulla that give rise to the neurovegetative 
symptoms of the PA (20). The second is an endogenous 
opioidergic system that modulates the suffocation alarm 
monitor and reduces social separation distress (30). The 
results cited above, suggesting that the antipanic action 
of 5-HT in the dPAG involves local endogenous opioids, 
indicate that this brain area may be the fulcrum of both 
the serotonergic and the opioidergic regulation of panic, 
highlighting once again the pivotal role of the dPAG in the 
pathophysiology of PD (3,13,14).
The present perspective on the pathophysiology of PD 
may have clinical implications, since it points to the use of 
opioid agonists in the management of PD. Although long-
term treatment with conventional opioids is questionable 
due to abuse liability, mixed agonists-antagonists or selec-
tive opioid-receptor agonists may be worth investigating for 
either alternative or coadjuvant treatment of PD.
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